MTNBNYSEPharmaceutical PreparationsUS GAAP · USD

Matinas BioPharma Holdings, Inc.

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing lipid nanocrystal (LNC) delivery technology and its lead product candidate MAT2203. The company is currently centered on advancing MAT2203 toward late-stage development and seeking a partner or transaction to monetize the asset and fund future work.

Ask about the company
Operating profit (EBIT)-7.0m USD
+71.7 %y/y
Net income-10.3m USD
+57.3 %y/y

Fiscal year 2025 · change from previous year

Development 2020–2025

-30-20-10010m USD2020: 0.16 m USD2020: EBIT -24 m USD20202021: 0.03 m USD2021: EBIT -25 m USD20212022: 3.2 m USD2022: EBIT -25 m USD20222023: 1.1 m USD2023: EBIT -24 m USD20232024: 1.1 m USD2024: EBIT -25 m USD20242025: EBIT -7.0 m USD2025-7.0
RevenueOperating profit (EBIT)

Business

Share of revenue
MAT220370 %

Lead lipid nanocrystal product candidate being advanced through clinical development and partnership discussions.

LNC Platform Technology20 %

Proprietary delivery platform intended to improve formulation, delivery and commercialization potential of drug assets.

R&D Services and Development Support10 %

Internal and outsourced research, clinical, CMC and regulatory work supporting pipeline advancement.

Customers

Matinas does not sell commercial pharmaceutical products today; its economic counterparties are primarily potential licensing partners, biotech/pharma collaborators, CROs and research vendors. The company’s near-term goal is to secure a well-funded third-party partner to advance MAT2203 into Phase 3 and potentially commercialize it after approval.

Pharmaceutical partnership candidates

Large or well-funded biotech/pharma companies that could license MAT2203 and fund Phase 3 development and commercialization.

Strategic licensing counterparties

Companies evaluating the LNC platform or related assets for non-dilutive licensing or acquisition.

Clinical research vendors

CROs, laboratories and consultants that provide trial design, execution, analysis and regulatory support.

Government and third-party funding sources

NIH and other non-dilutive funding providers that may support preclinical or clinical work.

Strategy

Matinas is prioritizing a partnership or licensing transaction for MAT2203 to secure non-dilutive capital and accelerate late-stage development. At the same time, it is conserving cash, evaluating additional strategic options and preserving flexibility to in-license assets or pursue a merger if that creates more value.

Partner MAT2203Short term

A funded partner can advance the asset faster and reduce Matinas' capital burden.

Preserve liquidityShort term

The company is loss-making and needs to extend runway while it seeks strategic options.

Broaden strategic optionalityMedium term

Additional assets or a merger could create value if MAT2203 monetization is delayed.

Geography

The company is headquartered in the United States and its disclosed operating footprint is centered on U.S.-based R&D, regulatory and financing activities. No country-level revenue disclosure is provided because Matinas is still pre-commercial and has not reported meaningful product sales.

Risks

Matinas is a pre-revenue biotech with a high dependence on external financing and successful partnering of MAT2203. Its business model concentrates risk in a single lead asset, while clinical, regulatory, dilution and warrant-related valuation risks can all materially affect results and liquidity.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Financing shortfall / going concern pressure1Dilution from equity financings2Warrant and preferred stock complexity5
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Financing shortfall / going concern pressureImpact: CriticalLikelihood: High

    The company expects continued losses and needs new capital to fund operations and trials.

    ExposureCash runwayAbility to continue as a going concern
  2. Dilution from equity financingsImpact: HighLikelihood: High

    Management may need to issue common stock or convertible securities to raise funds.

    Exposure: Shareholder ownership and capital structure

  3. MAT2203 development failure or delayImpact: High

    Value creation depends heavily on advancing the lead candidate into Phase 3 and beyond.

    Exposure: Pipeline concentration

  4. Partnering and licensing execution riskImpact: High

    The strategy relies on finding a capable third-party partner on acceptable terms.

    Exposure: Monetization of lead asset

  5. Warrant and preferred stock complexityImpact: MediumLikelihood: Low

    Recent financings included warrants and preferred stock that can affect reported earnings and dilution.

    Exposure: Valuation and share count

Accounting

Judgemental items
Warrant liability fair value

Liability-classified warrants are revalued each reporting period, creating non-cash gains or losses.

Impact: Can materially move other income/expense and net loss

Research and development expense timing

Clinical, CMC and regulatory costs are expensed as incurred and can fluctuate with trial activity.

Impact: Affects operating loss and quarter-to-quarter comparability

Goodwill and intangible impairment

Management must assess whether acquired intangible value remains recoverable.

Impact: Potential non-cash write-downs

Stock-based compensation

Employee and consultant equity awards are a meaningful non-cash cost for a development-stage biotech.

Impact: Raises operating expenses without cash outflow

Similar listed companies

Publicly listed companies with a comparable business focus.

Liminatus Pharma, Inc.

LIMNW · Biological Products, (No Diagnostic Substances)

LeonaBio, Inc.

LONA · Biological Products, (No Diagnostic Substances)

Zenas BioPharma, Inc.

ZBIO · Pharmaceutical Preparations

Dianthus Therapeutics, Inc.

DNTH · Pharmaceutical Preparations

Larimar Therapeutics, Inc.

LRMR · Pharmaceutical Preparations

GT Biopharma, Inc.

GTBP · Pharmaceutical Preparations

Last updated: 24/09/2026